Keunchil Park

73.0k total citations · 12 hit papers
567 papers, 27.4k citations indexed

About

Keunchil Park is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Keunchil Park has authored 567 papers receiving a total of 27.4k indexed citations (citations by other indexed papers that have themselves been cited), including 398 papers in Pulmonary and Respiratory Medicine, 385 papers in Oncology and 95 papers in Molecular Biology. Recurrent topics in Keunchil Park's work include Lung Cancer Treatments and Mutations (342 papers), Lung Cancer Research Studies (160 papers) and Lung Cancer Diagnosis and Treatment (105 papers). Keunchil Park is often cited by papers focused on Lung Cancer Treatments and Mutations (342 papers), Lung Cancer Research Studies (160 papers) and Lung Cancer Diagnosis and Treatment (105 papers). Keunchil Park collaborates with scholars based in South Korea, United States and France. Keunchil Park's co-authors include Myung‐Ju Ahn, Jin Seok Ahn, Jong‐Mu Sun, Se‐Hoon Lee, Johan Vansteenkiste, Filippo de Marinis, Joachim von Pawel, Jeeyun Lee, U. Gatzemeier and Yoon‐La Choi and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Keunchil Park

558 papers receiving 26.9k citations

Hit Papers

Phase III Study Comparing... 2008 2026 2014 2020 2008 2016 2009 2012 2012 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
    2008 2.5k citations Giorgio V. Scagliotti, Purvish Parikh et al. Journal of Clinical Oncology profile →
  2. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
    2016 2.1k citations Johan Vansteenkiste, Keunchil Park et al. profile →
  3. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
    2009 1.0k citations Joachim von Pawel, Keunchil Park et al. profile →
  4. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
    2012 776 citations Keunchil Park, Caicun Zhou et al. profile →
  5. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
    2012 611 citations Keunchil Park, Dae Ho Lee et al. Journal of Clinical Oncology profile →
  6. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
    2011 453 citations Joachim von Pawel, Keunchil Park et al. profile →
  7. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
    2018 336 citations Johan Vansteenkiste, Filippo de Marinis et al. profile →
  8. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
    2015 331 citations Keunchil Park, Martin Reck et al. profile →
  9. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
    2019 322 citations Jin Seok Ahn, Myung‐Ju Ahn et al. profile →
  10. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
    2021 165 citations Michael Boyer, Mehmet Alı Nahıt Şendur et al. Journal of Clinical Oncology profile →
  11. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer
    2021 162 citations Ki Hyeong Lee, Keunchil Park et al. profile →
  12. Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
    2022 119 citations Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Keunchil Park 17.9k 17.0k 6.2k 4.0k 2.8k 567 27.4k
Myung‐Ju Ahn 22.3k 1.2× 22.6k 1.3× 7.5k 1.2× 5.1k 1.3× 1.7k 0.6× 717 32.1k
Kazuhiko Nakagawa 22.1k 1.2× 20.8k 1.2× 9.9k 1.6× 4.4k 1.1× 2.0k 0.7× 815 32.3k
Enriqueta Felip 23.6k 1.3× 22.9k 1.3× 9.0k 1.5× 5.7k 1.4× 2.0k 0.7× 796 33.7k
Giorgio V. Scagliotti 17.1k 1.0× 19.6k 1.2× 8.4k 1.4× 5.3k 1.3× 1.5k 0.5× 480 29.7k
D. Ross Camidge 15.0k 0.8× 16.9k 1.0× 8.6k 1.4× 4.6k 1.1× 1.9k 0.7× 539 24.2k
David R. Spigel 14.4k 0.8× 9.9k 0.6× 5.0k 0.8× 2.9k 0.7× 2.3k 0.8× 611 20.0k
Federico Cappuzzo 16.9k 0.9× 16.9k 1.0× 7.0k 1.1× 4.3k 1.1× 1.8k 0.7× 360 24.6k
Luis Paz‐Ares 13.2k 0.7× 11.4k 0.7× 7.6k 1.2× 4.2k 1.1× 1.3k 0.5× 690 23.0k
Filippo de Braud 17.9k 1.0× 8.8k 0.5× 5.7k 0.9× 3.7k 0.9× 3.3k 1.2× 754 26.7k
Yoon‐Koo Kang 12.3k 0.7× 13.6k 0.8× 5.2k 0.8× 3.0k 0.8× 3.8k 1.4× 550 26.2k

Countries citing papers authored by Keunchil Park

Since Specialization
Citations

This map shows the geographic impact of Keunchil Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keunchil Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keunchil Park more than expected).

Fields of papers citing papers by Keunchil Park

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keunchil Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keunchil Park. The network helps show where Keunchil Park may publish in the future.

Co-authorship network of co-authors of Keunchil Park

This figure shows the co-authorship network connecting the top 25 collaborators of Keunchil Park. A scholar is included among the top collaborators of Keunchil Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keunchil Park. Keunchil Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pérol, M., Kōichi Goto, Benjamin Solomon, et al.. (2024). Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.. Journal of Clinical Oncology. 42(16_suppl). 8547–8547.
2.
Pérol, M., Benjamin Solomon, Kōichi Goto, et al.. (2024). CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer. Journal of Clinical Oncology. 42(21). 2500–2505. 5 indexed citations
3.
Kim, Hana, Sehhoon Park, Hyun Ae Jung, et al.. (2023). Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancer Research and Treatment. 55(4). 1104–1112. 14 indexed citations
4.
Park, Sehhoon, Yu Jung Kim, Young Joo Min, et al.. (2023). Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. Cancer. 130(4). 541–552. 15 indexed citations
5.
Drilon, Alexander, Vivek Subbiah, Oliver Gautschi, et al.. (2022). Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. Journal of Clinical Oncology. 41(2). 385–394. 119 indexed citations breakdown →
6.
7.
Nakagawa, Kazuhiko, Ernest Nadal, Edward B. Garon, et al.. (2021). RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 27(19). 5258–5271. 29 indexed citations
8.
Kim, Edward S., Barbara Melosky, Keunchil Park, Nobuyuki Yamamoto, & James Chih‐Hsin Yang. (2021). Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations. Future Oncology. 17(18). 2395–2408. 18 indexed citations
9.
Park, Keunchil, Gee‐Chen Chang, Giuseppe Curigliano, et al.. (2021). Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. Lung Cancer. 155. 127–135. 10 indexed citations
10.
Boyer, Michael, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, et al.. (2021). Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of Clinical Oncology. 39(21). 2327–2338. 165 indexed citations breakdown →
11.
Yu, Helena A., Luis Paz‐Ares, James Chih‐Hsin Yang, et al.. (2020). Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non–small Cell Lung Cancer. Clinical Cancer Research. 27(4). 992–1002. 31 indexed citations
12.
Lee, Min Ho, Kyung Rae Cho, Jung Won Choi, et al.. (2020). Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. Journal of Korean Neurosurgical Society. 64(2). 271–281. 11 indexed citations
13.
Kim, Kyung Hwan, Jinhyun Cho, Bo Mi Ku, et al.. (2019). The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clinical Cancer Research. 25(7). 2144–2154. 132 indexed citations
14.
Park, Sehhoon, Hayoon Lee, Boram Lee, et al.. (2019). DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. Journal of Thoracic Oncology. 14(9). 1640–1650. 58 indexed citations
15.
Wu, Yi‐Long, Victor Lee, Chong Kin Liam, et al.. (2018). Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer. 126. 1–8. 35 indexed citations
16.
Lee, Ji Yun, Jong‐Mu Sun, Sung Hee Lim, et al.. (2015). A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. Clinical Cancer Research. 22(9). 2139–2145. 28 indexed citations
17.
18.
Kim, Young-Wook, Jeong‐Hun Ko, Amir Abolhoda, et al.. (2012). The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor. Molecular Cancer Therapeutics. 11(3). 784–791. 144 indexed citations
19.
Scagliotti, Giorgio V., Purvish Parikh, Joachim von Pawel, et al.. (2008). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(21). 3543–3551. 2487 indexed citations breakdown →
20.
Park, Sarah, Jeeyun Lee, Young Hyeh Ko, et al.. (2007). The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 110(3). 972–978. 242 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Myung‐Ju Ahn Breakdown of academic impact, for papers by Kazuhiko Nakagawa Breakdown of academic impact, for papers by Enriqueta Felip Breakdown of academic impact, for papers by Giorgio V. Scagliotti Breakdown of academic impact, for papers by D. Ross Camidge Breakdown of academic impact, for papers by David R. Spigel Breakdown of academic impact, for papers by Federico Cappuzzo Breakdown of academic impact, for papers by Luis Paz‐Ares Breakdown of academic impact, for papers by Filippo de Braud Breakdown of academic impact, for papers by Yoon‐Koo Kang
Rankless by CCL
2026